The Patent Finder

DR. Falk Pharma GmbH

23 patents currently held · Updated Nov 20, 2026
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

0
Ending by 2030
Nov 2031
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Feb 6 to 28, 2027 · next Feb 6
  • 1 fee due Jun 26, 2027
    The maintenance fee for Use of nor-ursodeoxycholic acid for reducing liver fat (US 11,850,252) comes due Jun 26, 2027. Unpaid by Dec 27, 2027, it lapses early.
  • 1 fee due Jul 9, 2027
    The maintenance fee for ANTI-CD30L Antibodies and Uses Thereof (US 11,866,505) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.
  • 1 fee due Oct 7, 2027
    The maintenance fee for A method of treating pancreatitis using 1,4-benzoxazine derivatives. (US 10,611,756) comes due Oct 7, 2027. Unpaid by Apr 7, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 10,000,526Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
In force
 · USPTO record
In forceUSPTO record
US 9,512,167Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
In force
 · USPTO record
In forceUSPTO record
US 11,352,3343-(5-Chloro-2-Oxobenzo[D]OXAZOL-3(2H)-YL) Propanoic Acid Derivatives as Kmo Inhibitors
In force
 · Medium confidence
In forceMedium confidence
US 12,459,9063-(5-Chloro-2-Oxobenzo[D]OXAZOL-3(2H)-YL) Propanoic Acid Derivatives as Kmo Inhibitors
In force
 · Medium confidence
In forceMedium confidence
US 9,867,780Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus
In force
 · USPTO record
In forceUSPTO record
US 10,369,100Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus
In force
 · USPTO record
In forceUSPTO record
US 10,695,291Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus
In force
 · USPTO record
In forceUSPTO record
US 11,382,860Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus
In force
 · USPTO record
In forceUSPTO record
US 9,932,3283-(6-Alkoxy-5-Chlorobenzo[D]ISOXAZOL-3-YL)PROPANOIC Acid Useful as Kynurenine Monooxygenase Inhibitors
In force
 · High confidence
In forceHigh confidence
US 10,273,2323-(6-Alkoxy-5-Chlorobenzo[D]ISOXAZOL-3-YL)PROPANOIC Acid Useful as Kynurenine Monooxygenase Inhibitors
In force
 · Medium confidence
In forceMedium confidence
10 of 23 patents shown.
Pro members see all 23.
Pro members: see all 23 patents
Also on record, not counted in the 23: 2 patents in force now held by others · 5 lapsed for an unpaid fee · 10 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 pending · 1 abandoned · 2 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited